180 Wealth Advisors LLC Invests $120,000 in Veru Inc. (NASDAQ:VERU)

180 Wealth Advisors LLC bought a new stake in shares of Veru Inc. (NASDAQ:VERU) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 170,750 shares of the company’s stock, valued at approximately $120,000. 180 Wealth Advisors LLC owned approximately 0.12% of Veru as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Worth Venture Partners LLC bought a new position in Veru in the 4th quarter worth $616,000. AIGH Capital Management LLC bought a new position in Veru in the fourth quarter worth about $2,476,000. ADAR1 Capital Management LLC purchased a new stake in Veru in the fourth quarter worth about $360,000. Octagon Capital Advisors LP purchased a new position in shares of Veru during the 4th quarter worth approximately $2,736,000. Finally, Perceptive Advisors LLC raised its position in shares of Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock worth $4,021,000 after acquiring an additional 4,494,821 shares in the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Mitchell Shuster Steiner sold 63,379 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $1.23, for a total transaction of $77,956.17. Following the transaction, the chief executive officer now directly owns 6,942,709 shares of the company’s stock, valued at $8,539,532.07. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 181,970 shares of company stock valued at $250,075. Corporate insiders own 14.20% of the company’s stock.

Veru Trading Up 5.2 %

Shares of Veru stock opened at $0.84 on Friday. Veru Inc. has a 1 year low of $0.36 and a 1 year high of $1.92. The firm’s 50-day moving average is $1.15 and its 200 day moving average is $0.83.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Veru had a negative net margin of 265.27% and a negative return on equity of 130.13%. The firm had revenue of $4.14 million for the quarter, compared to the consensus estimate of $3.00 million. Equities analysts expect that Veru Inc. will post -0.27 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on VERU. Raymond James started coverage on Veru in a research report on Thursday, March 28th. They set an “outperform” rating and a $3.00 price target on the stock. Oppenheimer reiterated an “outperform” rating and issued a $5.00 price target (down from $7.00) on shares of Veru in a research note on Monday, April 15th. B. Riley started coverage on shares of Veru in a research note on Tuesday, May 14th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Veru in a research note on Monday, May 13th.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.